Pharsight

Horizant is owned by Azurity.

Horizant contains Gabapentin Enacarbil.

Horizant has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Horizant are:

US8048917

Horizant was authorised for market use on 06 April, 2011.

Horizant is available in tablet, extended release;oral dosage forms.

Horizant can be used as treatment of moderate-to-severe primary restless leg syndrome in adults, treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults, management of postherpetic neuralgia (phn) in adults.

The generics of Horizant are possible to be released after 10 June, 2029.

Application	Filing Date	Opposition Party	Legal Status
EP02744314A	2008-09-04	Breuer, Markus	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8048917	AZURITY	Prodrugs of GABA analogs, compositions and uses thereof	Nov, 2022 (6 months ago)
US6818787	AZURITY	Prodrugs of GABA analogs, compositions and uses thereof	Apr, 2025 (1 year, 10 months from now)
US8026279	AZURITY	Crystalline form of γ-aminobutyric acid analog	Nov, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034	AZURITY	Crystalline form of γ-aminobutyric acid analog	Jan, 2025 (1 year, 7 months from now)
US8114909	AZURITY	Treating or preventing restless legs syndrome using prodrugs of GABA analogs	Apr, 2026 (2 years from now)
US8795725	AZURITY	GABA analog prodrug sustained release oral dosage forms	Jun, 2029 (6 years from now)